Protagonist Therapeutics Inc (PTGX)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -78,955 | -127,393 | -125,551 | -64,850 | -77,878 |
| Revenue | US$ in thousands | 60,137 | 26,704 | 27,448 | 27,534 | 118 |
| Pretax margin | -131.29% | -477.06% | -457.41% | -235.53% | -65,998.31% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $-78,955K ÷ $60,137K
= -131.29%
Protagonist Therapeutics Inc's pretax margin, a measure of its profitability before taxes, has shown significant fluctuations over the past five years. The company's pretax margin was -131.29% in 2023, an improvement from the -477.06% and -457.41% recorded in 2022 and 2021, respectively. However, these figures still indicate that the company's expenses exceeded its revenues before accounting for taxes during these years.
In 2020, Protagonist Therapeutics Inc's pretax margin was -235.53%, showing a slight improvement from the previous year but still reflecting operational inefficiencies. The pretax margin in 2019 was notably at -65,998.31%, which may have been impacted by one-time expenses or accounting anomalies.
Overall, Protagonist Therapeutics Inc has shown a trend of struggling with generating profits before taxes in recent years, with fluctuating margins indicating operational challenges and potentially unsustainable business practices that may require further investigation and improvement.
Peer comparison
Dec 31, 2023